Revvity, Inc. (RVTY) News
Follow Revvity, Inc. (RVTY) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 49 public stories across 19 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
Analysts Raise Price Targets for Revvity After Q3 Earnings
Stifel Nicolaus, Goldman Sachs, JPMorgan and TD Cowen raised their Revvity price targets to $177, $160, $160 and $185, respectively.
EQUITY | Nov 04, 2026, 02:34 PM UTC
M
Revvity Announces Dividend of R$ 0.00918831200 per Unit
Revvity announced a first-quarter 2027 dividend of R$ 0.00918831200 per unit.
EQUITY | Nov 03, 2026, 08:32 PM UTC
M
Revvity set for best day in over 16 years after beating Q3 forecasts
Revvity is poised for its strongest one-day performance in more than 16 years after exceeding third-quarter forecasts.
EARNINGS | Nov 03, 2026, 06:06 PM UTC
M
Revvity shares reach 16-year high after third-quarter results top estimates
Revvity shares reached a 16-year high after third-quarter results topped expectations.
EARNINGS | Nov 03, 2026, 06:05 PM UTC
M
Revvity Shares Set for Best Day in Over 16 Years After Q3 Beat
Revvity shares are set for their best day in over 16 years after the company beat in the third quarter.
EARNINGS | Nov 03, 2026, 06:05 PM UTC
M
Revvity Shares Rise 11.4% After Q3 Revenue Beat, Guidance Raise
Revvity shares hit their highest level since April 2022 after the company reported a third-quarter revenue beat and raised full-year guidance.
EQUITY | Nov 03, 2026, 02:37 PM UTC
M
Revvity Reports Quarterly Results for Period Ended September 30
The headline provides no revenue, profit, EPS or other result figures.
EQUITY | Nov 03, 2026, 02:33 PM UTC
M
Revvity Executive Says Software Growth to Moderate to Mid-Teens in Q4
Revvity’s software business grew at a high-teens rate in Q3; an executive expects growth to moderate to mid-teens in Q4.
EARNINGS | Nov 03, 2026, 01:13 PM UTC
M
Revvity Reports Q3 Revenue of $728.9 Million, Updates 2026 Guidance
Revvity reported adjusted EPS of $1.38 for Q3 2026. It projects 2026 revenue of approximately $2.86 billion and adjusted EPS of $5.40 to $5.45.
EQUITY | Nov 03, 2026, 12:33 PM UTC
M
Revvity Raises Annual Profit Forecast as Q3 Results Beat
Revvity shares rise after the company raises its annual profit forecast and reports Q3 results that beat expectations.
EQUITY | Nov 03, 2026, 12:25 PM UTC
M
Revvity Shares Rise 11.6% Premarket After Q3 Revenue Beat, FY Guidance Raise
EQUITY | Nov 03, 2026, 11:46 AM UTC
M
Revvity Reports Q3 2026 Results, EPS of $0.56 and Revenue of $729 Million
Revvity reported continuing-operations GAAP EPS of $0.56, compared with $0.41 a year earlier. Revenue was $729 million.
EQUITY | Nov 03, 2026, 11:26 AM UTC
L
Revvity reports third-quarter adjusted EPS of $1.38
EARNINGS | Nov 03, 2026, 11:12 AM UTC
M
Revvity Q3 Revenue Beats Estimates, Raises FY Guidance
EQUITY | Nov 03, 2026, 11:11 AM UTC
M
Revvity Sees 2026 Pro Forma Revenue of About $2.86B
EARNINGS | Nov 03, 2026, 11:11 AM UTC
M
Revvity Expects 2026 Adjusted EPS of $5.40–$5.45
Revvity expects 2026 adjusted EPS of $5.40–$5.45, versus a FactSet estimate of $5.36.
EARNINGS | Nov 03, 2026, 11:11 AM UTC
M
Revvity Sees 2026 Adjusted EPS of $5.40-$5.45
EARNINGS | Nov 03, 2026, 11:08 AM UTC
M
Revvity Q3 Adjusted EPS USD 1.37 vs. IBES Estimate USD 1.3
EARNINGS | Nov 03, 2026, 11:02 AM UTC
M
Revvity Announces Third-Quarter 2026 Financial Results
EQUITY | Nov 03, 2026, 11:01 AM UTC
M
Revvity Reports Third-Quarter Earnings
EQUITY | Nov 03, 2026, 11:00 AM UTC
L
Revvity Reports Third-Quarter Net Income of $62.3 Million
EARNINGS | Nov 03, 2026, 11:00 AM UTC
M
Revvity Q3'26 Results Due Before Market Open November 3
Revvity is scheduled to report Q3'26 results before the market opens November 3.
EQUITY | Nov 02, 2026, 12:01 PM UTC
M
Revvity Q3'26 Results Scheduled for November 3
Revvity is scheduled to report Q3'26 results before the market opens. The source gives revenue and EPS estimates but their figures are omitted here.
EQUITY | Oct 27, 2026, 11:01 AM UTC
H
Revvity Nears 52-Week High, but This Analyst Thinks Stock Can Climb Another 20%
Revvity Inc. (NYSE: RVTY ) drew new bullish coverage Monday as William Blair initiated the stock with an Outperform rating, arguing that artificial intelligence could become a net tailwind for the company. Life Sciences
LIVE | Oct 06, 2026, 06:51 PM UTC
M
Revvity Schedules Q3 2026 Earnings Call for November 3
Revvity, Inc. will release its third quarter 2026 financial results before market open on November 3, 2026, and will host a conference call that day at 7:30 a.m. ET.
EQUITY | Oct 02, 2026, 12:00 PM UTC
L
Weekly Recap: Q2 revenue rise, higher FY guide and GSP T1D 3plex launch
Revvity, Inc. (NYSE:RVTY) shares hit a 52—week high after Q2 pro forma revenue of $730M and a raised FY guide to $2.83B—$2.86B, while the company expanded diagnostics with the SuperFlex prenatal test, automated T—SPOT.TB
EARNINGS | Sep 28, 2026, 11:05 AM UTC
H
Full Transcript: Revvity Q2 2026 Earnings Call
Revvity (NYSE: RVTY ) reported second-quarter financial results on Tuesday. The transcript from the company's second-quarter earnings call has been provided below. This content is powered APIs. For comprehensive financia
LIVE | Sep 25, 2026, 09:22 AM UTC
L
Biotech Stocks At 52-Week Highs - CDNA +13%, GRAL +15%, TWST +16%, ADPT, RVTY
WASHINGTON (dpa-AFX) - The following biotech stocks reached a 52-week high on September 24, 2026, driven by key catalysts such as reaching certain regulatory milestones or results from clinical trials.CareDx Inc. (CDNA)C
NEWS | Sep 25, 2026, 08:54 AM UTC
L
RVTY - Revvity Launches IVDR-Certified Solution for Early Detection of Type 1 Diabetes
RVTY - Revvity Launches IVDR-Certified Solution for Early Detection of Type 1 Diabetes
NEWS | Sep 24, 2026, 12:04 PM UTC
L
Revvity, Inc. (RVTY) Launches CE-IVDR T1D Screening Kit in Europe
Revvity launched the GSP T1D 3plex kit, a fully automated, CE—IVDR—certified autoantibody test for early T1D risk detection, processed on its GSP instrument. It will be available in Europe and other CE IVD markets; not F
REGULATION | Sep 24, 2026, 12:00 PM UTC
L
Revvity Launches IVDR-Certified Solution for Early Detection of Type 1 Diabetes
Revvity, Inc. (NYSE: RVTY) today announced the launch of the GSP® T1D 3plex kit, a fully automated, CE-IVDR-certified, multiplex autoantibody (AAb) detection solution to enable population-wide screening programs that ide
NEWS | Sep 24, 2026, 12:00 PM UTC
M
Revvity reports Q2 revenue, raises FY guide; expands diagnostics
Revvity (RVTY) reported Q2 revenue of $730M (pro forma +4%), raised FY guidance to $2.83–$2.86B (pro forma ~4–5% growth), and launched SuperFlex prenatal testing, expanded preeclampsia diagnostic coverage, and moved the
EQUITY | Sep 21, 2026, 11:29 AM UTC
M
Biotech shares hit 52-week highs; MNOV, RVTY, TLX jump
Several biotech stocks reached 52-week highs on Sept. 15, 2026, including MediciNova (MNOV), Revvity (RVTY), and Telix (TLX), with the report attributing strength to gains on certain clinical or financial results.
EQUITY | Sep 16, 2026, 05:36 AM UTC
L
RVTY: Diagnostics and life sciences growth, AI-driven innovation, and strong backlog fuel positive outlook
The company reported strong Q2 results, driven by diagnostics and a recovering life sciences segment, with significant backlog in high-content screening instruments and robust growth in China. Software innovation and AI
EARNINGS | Sep 15, 2026, 02:35 PM UTC
L
RVTY: Strong Q2 results, innovation, and AI-driven demand set the stage for Revvity's growth
Revvity reported better-than-expected Q2 results, driven by strong diagnostics and a robust backlog in life sciences, especially high-content screening instruments. Innovation in software and AI integration, along with o
EARNINGS | Sep 15, 2026, 02:06 PM UTC
H
RVTY raises margin guidance as AI-driven demand lifts growth
AI-driven demand is accelerating growth in high-content screening and software, while a tuck-in acquisition strengthens the reagents portfolio. Diagnostics and reproductive health segments remain robust, and margin guida
EARNINGS | Sep 09, 2026, 02:24 PM UTC
L
UBS assumes neutral on Revvity, raises price target to $140
UBS coverage on Revvity is assumed at a neutral rating versus a previous buy, with the price target raised to $140.00 per share from $120.00.
EQUITY | Sep 09, 2026, 02:06 PM UTC
H
RVTY raises margin guidance on AI-driven demand and cost initiatives
RVTY cites AI-driven demand for high-content screening and software innovation, plus robust diagnostics and reproductive health growth. It also says a tuck-in reagents acquisition supports the reagents business, and rais
EARNINGS | Sep 09, 2026, 01:45 PM UTC
L
Revvity to acquire Human Cell Design
Content provided by Seeking Alpha is intended for information purposes only, and that Seeking Alpha does not offer any personalist investment advice and is not a licensed securities dealer, broker, US investment adviser
MNA | Sep 09, 2026, 10:51 AM UTC
M
Revvity to acquire Human Cell Design to advance metabolic disease models
Revvity plans to acquire Human Cell Design to advance human-relevant cell models for metabolic disease drug discovery.
MNA | Sep 09, 2026, 10:04 AM UTC
L
Revvity files additional transaction terms not disclosed
Revvity reports additional terms of transaction are not disclosed for RVTY.
EQUITY | Sep 09, 2026, 10:01 AM UTC
L
Revvity price target raised to $165 by Keybanc
Keybanc raised its Revvity price target to $165.00/share from $125.00, according to Benzinga ratings actions.
EQUITY | Sep 04, 2026, 01:27 PM UTC
L
RBC Capital starts Revvity at Sector Perform
RBC Capital initiated coverage of Revvity with a Sector Perform rating.
EQUITY | Sep 01, 2026, 12:13 PM UTC
H
Transcript: Revvity Q2 2026 Earnings Conference Call
Revvity (NYSE: RVTY ) held its second-quarter earnings conference call on Tuesday. Below is the complete transcript from the call. APIs provide real-time access to earnings call transcripts and financial data. Visit to l
EARNINGS | Aug 04, 2026, 12:34 PM UTC
H
Revvity Raises FY2026 Adj EPS Guidance from $5.20-$5.30 to $5.30-$5.40 vs $5.27 Est; Raises FY2026 Sales Guidance from $2.810B-$2.840B to $2
Revvity (NYSE: RVTY ) raises FY2026 Adj EPS guidance from $5.20-$5.30 to $5.30-$5.40 vs $5.27 analyst estimate. Raises FY2026 sales outlook from $2.810 billion-$2.840 billion to $2.830 billion-$2.860 billion vs $2.858 bi
EARNINGS | Aug 04, 2026, 10:02 AM UTC
H
RVTY - Revvity Announces Financial Results for the Second Quarter of 2026
RVTY - Revvity Announces Financial Results for the Second Quarter of 2026
EARNINGS | Aug 04, 2026, 10:01 AM UTC
L
Revvity Declares Quarterly Dividend
Revvity declares quarterly dividend
EQUITY | Jul 31, 2026, 08:10 PM UTC
L
Evercore ISI Adjusts Price Target on Revvity to $125 From $110
() -- Revvity (RVTY) has an average rating of overweight and mean price target of $114.21, according to analysts polled by FactSet. ( covers equity, commodity and economic research from major banks and research firms in
EQUITY | Jul 06, 2026, 01:10 PM UTC
M
RVTY: Bernstein Reinstates
Bernstein reinstates Market Perform on Revvity with a $115 price target
EQUITY | Jun 26, 2026, 01:18 PM UTC